Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 5
2007 4
2008 5
2009 7
2010 6
2011 11
2012 18
2013 18
2014 16
2015 12
2016 22
2017 14
2018 12
2019 20
2020 44
2021 46
2022 31
2023 30
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Deferiprone in Parkinson's Disease.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group. Devos D, et al. Among authors: moreau c. N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254. N Engl J Med. 2022. PMID: 36449420 Clinical Trial.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management.
Geroin C, Artusi CA, Nonnekes J, Aquino C, Garg D, Dale ML, Schlosser D, Lai Y, Al-Wardat M, Salari M, Wolke R, Labou VT, Imbalzano G, Camozzi S, Merello M, Bloem BR, Capato T, Djaldetti R, Doherty K, Fasano A, Tibar H, Lopiano L, Margraf NG, Moreau C, Ugawa Y, Bhidayasiri R, Tinazzi M; International Parkinson and Movement Disorders Society Task Force on Postural Abnormalities. Geroin C, et al. Among authors: moreau c. Mov Disord. 2023 May;38(5):732-739. doi: 10.1002/mds.29377. Epub 2023 Apr 20. Mov Disord. 2023. PMID: 37081741 No abstract available.
Virtually reducing fall risk in Parkinson disease.
Moreau C, Barton BR, Devos D. Moreau C, et al. Neurology. 2017 Oct 24;89(17):1762-1763. doi: 10.1212/WNL.0000000000004581. Epub 2017 Sep 27. Neurology. 2017. PMID: 28954881 No abstract available.
Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group. Meissner WG, et al. N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323. N Engl J Med. 2024. PMID: 38598572 Clinical Trial.
Intracerebroventricular dopamine for Parkinson's disease.
Devos D, Devedjian JC, Moreau C. Devos D, et al. Among authors: moreau c. Oncotarget. 2017 Jul 11;8(28):45034-45035. doi: 10.18632/oncotarget.17596. Oncotarget. 2017. PMID: 28484085 Free PMC article. No abstract available.
Overview on wearable sensors for the management of Parkinson's disease.
Moreau C, Rouaud T, Grabli D, Benatru I, Remy P, Marques AR, Drapier S, Mariani LL, Roze E, Devos D, Dupont G, Bereau M, Fabbri M. Moreau C, et al. NPJ Parkinsons Dis. 2023 Nov 2;9(1):153. doi: 10.1038/s41531-023-00585-y. NPJ Parkinsons Dis. 2023. PMID: 37919332 Free PMC article. Review.
Iron as a therapeutic target for Parkinson's disease.
Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group. Moreau C, et al. Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. Mov Disord. 2018. PMID: 29380903 Review. No abstract available.
297 results